Company Overview of Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukem...
111 West Lemon Avenue
Monrovia, CA 91016
Founded in 1997
Key Executives for Xencor, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $516.7K
Vice President of Finance and Secretary
Total Annual Compensation: $327.4K
Chief Medical Officer and Senior Vice President
Total Annual Compensation: $460.6K
Chief Scientific Officer and Senior Vice President of Research
Total Annual Compensation: $370.8K
Chief Business Officer
Total Annual Compensation: $326.5K
Compensation as of Fiscal Year 2016.
Xencor, Inc. Key Developments
INmune Bio, Inc. Licenses INB03 from Xencor, Inc
Oct 10 17
INmune Bio, Inc. announced that it has licensed INB03, a novel innate immune system check-point inhibitor that targets Myeloid Derived Suppressor Cells, from Xencor, Inc. Myeloid Derived Suppressor Cells (MDSC) of the innate immune system are often increased in patients with cancer. The level of MDSC in the blood or the tumor microenvironment predict severity of disease, risk of dying from the cancer, and the failure of other immunotherapy treatment strategies such as currently available check point inhibitors. The MDSC secrete immunosuppressive cytokines that protect the tumor from attack by the patient's immune system. Strategies that target MDSC are needed to continue to make progress in the treatment of cancer.
Xencor, Inc. Presents at 2017 BIO Investor Forum, Oct-17-2017 08:30 AM
Sep 29 17
Xencor, Inc. Presents at 2017 BIO Investor Forum, Oct-17-2017 08:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Edgardo Baracchini, Chief Business Officer.
Xencor, Inc. Presents at LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology, Sep-28-2017 08:30 AM
Sep 20 17
Xencor, Inc. Presents at LEERINK Partners Roundtable Series on Rare Disease and Immuno-Oncology, Sep-28-2017 08:30 AM. Venue: Lotte New York Palace, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|